结核感染试验免疫反应强度与短期结核病风险的关联:前瞻性队列研究
在马达加斯加和喀麦隆开展的前瞻性队列研究纳入1659名近期暴露于肺结核的家庭接触者,其中1089名纳入预后分析,随访18个月。结果显示基线免疫反应强度较高与短期进展风险增加相关,结核菌素皮肤试验硬结≥14 mm的调整风险比为4.00,T-SPOT.TB panel A应答≥130 spots的调整风险比为5.86;但个体层面无法区分感染与早期疾病。
要点
- 结核感染试验的定性阳性对短期进展的预后区分能力有限。
- 结核菌素皮肤试验硬结≥14 mm与短期进展风险增加独立相关(aHR 4.00)。
- T-SPOT.TB panel A应答≥130 spots与短期进展风险增加独立相关(aHR 5.86)。
核心结论
- 结核感染试验测量的免疫反应强度与短期进展风险相关,但个体层面无法区分感染与早期疾病。
- 基于反应强度的解读可能改善风险分层,支持高发病率地区更高效的结核预防策略。
研究设计与样本
- 基线分析估计筛查队列中结核菌素皮肤试验和/或干扰素-γ释放试验阳性的患病率。
- 预后分析在预设分析集中进行,纳入年龄≥5岁、筛查时无症状、基线未接受结核预防治疗、基线免疫数据完整且随访完整的参与者,共1089人。
- 使用多变量Poisson和Cox比例风险模型评估基线免疫反应强度与 incident 结核的关联,调整年龄、性别和国家。
- 使用决策分析模型探索阈值指导的预防策略在马达加斯加的健康和经济影响。
主要发现
- 共纳入1659名家庭接触者,其中1089名纳入预后分析。
- 随访期间30名参与者出现症状性、微生物学确诊的结核,发病率为18.4/1000人年。
- 定性试验阳性显示有限的预后区分能力。
- 结核菌素皮肤试验硬结≥14 mm与进展相关(调整风险比4.00;95% CI 1.58-10.11)。
- T-SPOT.TB panel A应答升高(≥130 spots)与风险增加相关(调整风险比5.86;95% CI 2.40-14.35)。
临床怎么用
- 在高发病率地区,可考虑结合结核感染试验的免疫反应强度(如结核菌素皮肤试验硬结≥14 mm或T-SPOT.TB panel A≥130 spots)对近期暴露的家庭接触者进行风险分层。
- 基于反应强度阈值的解读可能优化预防性治疗的靶向人群,但个体层面不能仅凭反应强度区分感染与早期疾病。
局限性
- 研究仅在马达加斯加和喀麦隆两个高发病率国家进行,外推需谨慎。
- 预后分析排除了年龄<5岁、筛查时有症状、基线接受预防治疗或数据不完整的参与者,可能存在选择偏倚。
- 随访期间结核事件数较少(30例),限制统计效能和亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether the magnitude of immune responses measured by tuberculosis infection tests is associated with short-term risk of microbiologically confirmed tuberculosis. METHODS: Between December 2020 and December 2022, we conducted a prospective observational cohort study in Madagascar and Cameroon among household contacts recently exposed to pulmonary tuberculosis. Baseline analyses estimated the prevalence of tuberculin skin test and/or interferon-γ release assay positivity in the screening cohort. Participants were followed for 18 months. Prognostic analyses were performed in a prespecified analytic dataset including participants aged ≥5 years without symptoms at screening, not receiving tuberculosis preventive treatment at baseline, with complete baseline immunological data and complete follow-up. Associations between baseline immune-response magnitude and incident tuberculosis were evaluated using multivariable Poisson and Cox proportional hazards models adjusted for age, sex, and country. A decision-analytic model was used to explore the health and economic implications of threshold-guided preventive strategies in Madagascar. RESULTS: Among 1659 household contacts enrolled, 1089 were included in prognostic analyses. During follow-up, 30 participants developed symptomatic, microbiologically confirmed tuberculosis, corresponding to an incidence rate of 18.4 per 1000 person-years. Qualitative test positivity showed limited prognostic discrimination. In contrast, higher baseline immune-response magnitude was associated with increased short-term risk. A tuberculin skin test induration ≥14 mm was associated with progression (adjusted hazard ratio, 4.00; 95% CI, 1.58-10.11). Elevated T-SPOT.TB panel A responses (≥130 spots) were also associated with increased risk (adjusted hazard ratio, 5.86; 95% CI, 2.40-14.35). Cost-effectiveness analyses showed that threshold-guided strategies modified both the number of individuals eligible for preventive treatment and economic outcomes. CONCLUSIONS: Immune-response magnitude measured by tuberculosis infection tests was associated with short-term progression risk but did not distinguish infection from early disease at the individual level. Magnitude-informed interpretation of existing tests may improve risk stratification and support more efficient tuberculosis prevention strategies in high-incidence settings.
引用
- Ratovoson R, Donkeng V, Ranaivomanana P, et al. Association between immune-response magnitude to tuberculosis infection tests and short-term disease risk: a prospective cohort study. Clin Microbiol Infect. 2026. PMID: 42320712. doi:10.1016/j.cmi.2026.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。